医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Umami Information Center Holds the Third Annual Umami Lecture in New York

2015年05月07日 PM09:00
このエントリーをはてなブックマークに追加


 

NEW YORK

The Umami Information Center, an international non-profit organization dedicated to teaching umami, a savory taste known as the fifth taste, organized the third installment of the Umami Lecture at the Culinary Institute of America in New York.

Dr. Ninomiya lecturing students at the Umami Lecture at the Culinary Institute of America in New Yor ...

Dr. Ninomiya lecturing students at the Umami Lecture at the Culinary Institute of America in New York (Photo: Business Wire)

Along with the wide-spread trend of Japanese cooking, umami, pleasant savory taste of dashi soup stocks, has also attained worldwide recognition. However, not many food professionals know what umami really is and how to use it in the kitchen.

Adding to lectures about functions of dashi and umami components, and about how umami contributes to health, speakers of this year discussed difference between the Western and the Japanese stocks as well as the cooking methods that can increase the amount of umami in foods.

The three speakers were, the director of the Center and umami specialists, Dr. Kumiko Ninomiya, Chef Takuji Takahashi from the Japanese restaurant in Kyoto “Kinobu” in collaboration with the also Kyoto Chef Soichiro Hidari from “Tatsumiya,” and the food technologists Dr. Ali Bouzari, co-founder of Pilot R+D in Northern California.

Additional information about umami seminar at Culinary Institute of America can be found at http://www.umamiinfo.com/2015/04/umami-lecture-in-new-york.php.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150507005002/en/

CONTACT

Umami Information Center, Tokyo, Japan
Mio Kuriwaki, +81-3-3222-0235
info@umamiinfo.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer
  • Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy
  • No Dogs Left Behind Meat Market Survivors Coming Home
  • Takeda’s Maribavir Phase 3 Clinical Trial Met Primary Endpoint of Superiority to Conventional Antiviral Therapy in Transplant Recipients With Refractory, With or Without Resistance, Cytomegalovirus Infection/Disease
  • Modra Pharmaceuticals于2021 ASCO GU年会公布其转移性前列腺癌IIb期临床试验初步数据